Andrew Aw

468 total citations · 1 hit paper
21 papers, 272 citations indexed

About

Andrew Aw is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Andrew Aw has authored 21 papers receiving a total of 272 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 16 papers in Pathology and Forensic Medicine and 9 papers in Hematology. Recurrent topics in Andrew Aw's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (16 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Andrew Aw is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (16 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Andrew Aw collaborates with scholars based in Canada, United States and Australia. Andrew Aw's co-authors include Jennifer R. Brown, Jason Tay, Marc Carrier, Sheryl McDiarmid, Versha Banerji, Carolyn Owen, Sunita R. Setlur, Reina Improgo, Charles Lee and Siddha Kasar and has published in prestigious journals such as New England Journal of Medicine, Blood and Clinical Cancer Research.

In The Last Decade

Andrew Aw

18 papers receiving 266 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

2025 21 citations Jennifer R. Brown, John F. Seymour et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Aw Canada	9	144	106	79	71	59	21	272
Bosko Andjelic Serbia	12	87 0.6×	244 2.3×	17 0.2×	24 0.3×	55 0.9×	37	359
Jodi V. Mones United States	8	41 0.3×	25 0.2×	17 0.2×	41 0.6×	84 1.4×	21	283
M. Martín Jiménez Spain	10	21 0.1×	12 0.1×	30 0.4×	133 1.9×	68 1.2×	56	323
Simon Soudet France	8	43 0.3×	9 0.1×	10 0.1×	65 0.9×	41 0.7×	27	235
F. Espósito Spain	8	15 0.1×	38 0.4×	14 0.2×	32 0.5×	22 0.4×	24	216
Zdravko Mitrović Croatia	10	95 0.7×	160 1.5×	7 0.1×	20 0.3×	4 0.1×	30	255
Lucía López‐Anglada Spain	9	75 0.5×	24 0.2×	5 0.1×	11 0.2×	23 0.4×	14	245
Maria Anna Siciliano Italy	7	19 0.1×	15 0.1×	10 0.1×	55 0.8×	17 0.3×	12	176
Monica Castelli Italy	5	50 0.3×	19 0.2×	3 0.0×	20 0.3×	83 1.4×	7	235
Anne O. Rodriguez United States	7	8 0.1×	29 0.3×	22 0.3×	30 0.4×	130 2.2×	8	335

Countries citing papers authored by Andrew Aw

Since Specialization

Citations

This map shows the geographic impact of Andrew Aw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Aw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Aw more than expected).

Fields of papers citing papers by Andrew Aw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Aw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Aw. The network helps show where Andrew Aw may publish in the future.

Co-authorship network of co-authors of Andrew Aw

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Aw. A scholar is included among the top collaborators of Andrew Aw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Aw. Andrew Aw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Jennifer R., John F. Seymour, Wojciech Jurczak, et al.. (2025). Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. New England Journal of Medicine. 392(8). 748–762. 21 indexed citations breakdown →

Brown, Jennifer R., John F. Seymour, Wojciech Jurczak, et al.. (2024). Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial. Blood. 144(Supplement 1). 1009–1009. 6 indexed citations

Banerji, Versha, Andrew Aw, Nicole Laferriere, et al.. (2024). Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice. Leukemia & lymphoma. 65(5). 609–617.

Lachaîne, Jean, et al.. (2023). Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. Current Oncology. 30(5). 4483–4498. 9 indexed citations

Owen, Carolyn, Versha Banerji, Nathalie A. Johnson, et al.. (2023). Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 133. 107372–107372. 2 indexed citations

Owen, Carolyn, Versha Banerji, Nathalie A. Johnson, et al.. (2023). Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leukemia Research. 125. 107016–107016. 9 indexed citations

Aw, Andrew, et al.. (2022). Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study. Blood. 140(Supplement 1). 12425–12426.

Aw, Andrew, Lisa Duffett, Lothar Huebsch, et al.. (2021). To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report. Clinical Lymphoma Myeloma & Leukemia. 21(6). e493–e496. 1 indexed citations

Seung, Soo Jin, et al.. (2021). Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario. Current Oncology. 28(6). 4832–4844. 10 indexed citations

10.

Bhella, Sita, Andrew Aw, Christopher Bredeson, et al.. (2020). First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma. Current Oncology. 27(6). 632–644. 2 indexed citations

11.

Seung, Soo Jin, et al.. (2020). PCN350 USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF CANADIANS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Value in Health. 23. S86–S86. 1 indexed citations

12.

Banerji, Versha, et al.. (2020). Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia. Current Oncology. 27(6). 645–655. 5 indexed citations

13.

Hamdan, Alhafidz, et al.. (2019). OS10.5 Outcome of unresectable de novo IDH wild-type GBM: A decade analysis of factors influencing survival. Neuro-Oncology. 21(Supplement_3). iii21–iii21.

14.

Skeith, Leslie, Andrew Aw, Julia Hews‐Girard, & Natalia Rydz. (2017). A case that illustrates the challenges of managing pregnant patients with antithrombin deficiency: More questions than answers. Thrombosis Research. 157. 1–6. 4 indexed citations

15.

Aw, Andrew & Jennifer R. Brown. (2017). Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs & Aging. 34(7). 509–527. 32 indexed citations

16.

Aw, Andrew & Jennifer R. Brown. (2017). The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia & lymphoma. 58(10). 2287–2297. 9 indexed citations

17.

Yu, Lijian, Haesook T. Kim, Siddha Kasar, et al.. (2016). Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clinical Cancer Research. 23(3). 735–745. 62 indexed citations

18.

Aw, Andrew, Mitchell Sabloff, Dawn Sheppard, et al.. (2016). Evaluation of an Outpatient Model for Treatment of Acute Myeloid Leukemia. Journal of Hematology. 5(1). 1–7. 2 indexed citations

19.

Aw, Andrew, Kathryn Coyle, Isabelle Bence‐Bruckler, Christopher Bredeson, & Doug Coyle. (2016). Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis. Blood. 128(22). 1186–1186. 4 indexed citations

20.

Aw, Andrew, et al.. (2012). Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. Thrombosis Research. 130(3). 323–326. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact